120 related articles for article (PubMed ID: 30943166)
1. [Which follow-up for innovative treatments?].
Campana-Salort E; Espil-Taris C; Prigent H; de Antonio M; Lebrun-Vignes B; Tiffreau V; Honnet G
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():54-56. PubMed ID: 30943166
[No Abstract] [Full Text] [Related]
2. [Late-onset Pompe disease: the lessons drawn from the use of Myosime
Laforêt P
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():18-21. PubMed ID: 30943155
[No Abstract] [Full Text] [Related]
3. Sixty six-month follow-up of muscle power and respiratory function in a case with adult-type Pompe disease treated with enzyme replacement therapy.
Isayama R; Shiga K; Seo K; Azuma Y; Araki Y; Hamano A; Takezawa H; Kuriyama N; Takezawa N; Mizuno T; Nakagawa M
J Clin Neuromuscul Dis; 2014 Jun; 15(4):152-6. PubMed ID: 24872213
[TBL] [Abstract][Full Text] [Related]
4. Pompe disease: current state of treatment modalities and animal models.
Geel TM; McLaughlin PM; de Leij LF; Ruiters MH; Niezen-Koning KE
Mol Genet Metab; 2007 Dec; 92(4):299-307. PubMed ID: 17826266
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives.
van der Ploeg AT
Eur Respir J; 2005 Dec; 26(6):984-5. PubMed ID: 16319324
[No Abstract] [Full Text] [Related]
6. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
[TBL] [Abstract][Full Text] [Related]
7. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
[TBL] [Abstract][Full Text] [Related]
8. [The organization of pharmacovigilance in France, in Europe and worldwide - From label to delivery of an innovative treatment: what a journey! (3)].
Lebrun-Vignes B
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():37-39. PubMed ID: 30943161
[No Abstract] [Full Text] [Related]
9. Acid maltase deficiency presenting with a myopathy and exercise induced urinary incontinence in a 68 year old male.
Chancellor AM; Warlow CP; Webb JN; Lucas MG; Besley GT; Broadhead DM
J Neurol Neurosurg Psychiatry; 1991 Jul; 54(7):659-60. PubMed ID: 1895140
[No Abstract] [Full Text] [Related]
10. Pompe disease in infants and children.
Kishnani PS; Howell RR
J Pediatr; 2004 May; 144(5 Suppl):S35-43. PubMed ID: 15126982
[No Abstract] [Full Text] [Related]
11. Pompe disease: a neuromuscular disease with respiratory muscle involvement.
Mellies U; Lofaso F
Respir Med; 2009 Apr; 103(4):477-84. PubMed ID: 19131232
[TBL] [Abstract][Full Text] [Related]
12. Assessing the performance characteristics of signals used by a clinical event monitor to detect adverse drug reactions in the nursing home.
Handler SM; Hanlon JT; Perera S; Saul MI; Fridsma DB; Visweswaran S; Studenski SA; Roumani YF; Castle NG; Nace DA; Becich MJ
AMIA Annu Symp Proc; 2008 Nov; 2008():278-82. PubMed ID: 18998853
[TBL] [Abstract][Full Text] [Related]
13. FDA balks at Myozyme scale-up.
Mack G
Nat Biotechnol; 2008 Jun; 26(6):592. PubMed ID: 18536660
[No Abstract] [Full Text] [Related]
14. Playing competitive basketball in face of late-onset pompe disease.
Porta F; Pagliardini V; Roasio L; Biamino E; Spada M
Muscle Nerve; 2015 Feb; 51(2):302-3. PubMed ID: 25399823
[No Abstract] [Full Text] [Related]
15. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
Williams JC; Murray AK
Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
[No Abstract] [Full Text] [Related]
16. First treatment for Pompe disease.
FDA Consum; 2006; 40(4):3. PubMed ID: 17245826
[No Abstract] [Full Text] [Related]
17. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement for infantile Pompe disease: the first step toward a cure.
Wagner KR
Neurology; 2007 Jan; 68(2):88-9. PubMed ID: 17210887
[No Abstract] [Full Text] [Related]
19. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
Illés Z; Várdi Visy K
Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
[TBL] [Abstract][Full Text] [Related]
20. [Pompe's disease].
Laforêt P
Rev Med Interne; 2007 Dec; 28 Suppl 4():S290-1. PubMed ID: 18029059
[No Abstract] [Full Text] [Related]
[Next] [New Search]
